Spine surgeons validated clinical and economic benefits of an entirely synthetic solution in lateral lumbar fusions SAN DIEGO, July 26, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader ...
- Attrax Putty is now the first and only ceramic bone graft substitute supported by Level I evidence to demonstrate non-inferior fusion performance compared to autograft(1) - The trial enrolled 100 ...
Jan 25 (Reuters) - Medical device company NuVasive Inc. said it acquired bone grafting technology from privately held, California-based Radius Medical LLC for about $16 million in cash and stock. The ...
DUBLIN, April 15, 2020 /PRNewswire/ -- The "Orthobiologics for Bone Repair and Regeneration" report has been added to ResearchAndMarkets.com's offering. Over the forecast period covered by this report ...
NuVasive, Inc. NUVA recently announced the receipt of the FDA 510(k) approval for expanded indications of use for Attrax Putty, with its wide-ranging thoracolumbar interbody portfolio for spine ...
Please provide your email address to receive an email when new articles are posted on . Use of biphasic calcium-phosphate was a successful substitute as a standalone bone graft for autograft in ...
The global demineralized bone matrix (DBM) market is experiencing sustained expansion as it solidifies its role as a vital component in orthopedic and regenerative medicine. Valued at USD 1.83 billion ...
SAN DIEGO, March 10, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback